Trial Profile
Low Molecular Weight Heparin, Enoxaparin sodium, to Prevent Adverse Maternal and Perinatal Outcomes in Women With Previous Severe Preeclampsia at Less Than 34 Weeks' Gestation. A Prospective Randomized Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Aspirin (Primary) ; Enoxaparin sodium (Primary)
- Indications Embolism and thrombosis; Preeclampsia
- Focus Therapeutic Use
- Acronyms HEPEPE; NOH-PE; NOHA
- 01 Nov 2016 Results published in the Obstetrics and Gynecology
- 06 Oct 2016 Primary endpoint has not been met. (The primary outcome is a composite morbidity that may occur : maternal death, or perinatal death, or preeclampsia, or abruptio placenta, or fetal growth restriction. [ Time Frame: from randomization until one month after the delivery ] [ Designated as safety issue: No ]), according to results published in the Obstetrics and Gynecology.
- 06 Oct 2016 Results published in the Obstetrics and Gynecology